Lupin's Generic Spiriva Launch Delayed As FDA Action Expected By August
Medisol Acquisition To Push Injectables Growth
Lupin has pushed the launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables
You may also be interested in...
Scrip examines Torrent Pharma and Strides Pharma’s divergent strategies and Q4 financial performance in the US and India while presenting an infographic to compare market-wise metrics
Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.
Two acquisitions of brands in as many months, Lupin has stepped up its game in the Americas. A buyout of nine established Bausch Health brands follows rights to two from Sunovion. While it awaits news on generic(g) Spiriva, the launch of gPerforomist will help expand Lupin’s respiratory franchise